Canada markets close in 13 minutes

Hemostemix Inc. (HEM.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.0550+0.0050 (+10.00%)
As of 03:47PM EDT. Market open.

Hemostemix Inc.

707-7th Avenue SW
Suite 1150
Calgary, AB T2P 3H6
Canada

https://hemostemix.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Thomas A. Smeenk B.A., BA HonsCo-Founder, President, CEO & Director308kN/A1962
Ms. Christina Wu CPAInterim Chief Financial Officer65.38kN/AN/A
Mr. Peter PavlinVice President of OperationsN/AN/AN/A
Dr. Fraser C. Henderson Sr., M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

Corporate Governance

Hemostemix Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.